Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Second Genome, Inc

  • Karim Dabbagh, Second Genome

Second Genome has assembled a one-of-a-kind drug discovery platform that integrates microbiome and host biology for the identification of novel targets and drugs. This approach is based on understanding microbial community composition and its function in healthy and diseased conditions. Our powerful data analysis techniques enable the identification of microbes and microbial biomarkers that influence a given disease state. Combined with our expertise in drug development, our team has built the foundation for the rapid discovery of new therapeutic options for patients in a numerous microbiome-related diseases.

Second Genome’s microbiome modulating discovery platform allows us to generate and evaluate small molecules, peptide biologic and bacterial strains that modulate microbe-microbe and microbe-human interactions. By integrating our in vivo models with our in silico analyses we are able to understand how these compounds improve health and eliminate disease.

  • Date:Tuesday, February 12
  • Time:9:15 AM - 9:30 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23543
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Company introduction and presentation
  • Company Website:https://www.secondgenome.com
  • Company HQ City:South San Francisco
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$67M
  • CEO/Top Company Official:Karim Dabbagh
  • Year Founded:2010
  • Main Therapeutic Focus:Platform for Therapeutics
  • Lead Product in Development:SGM-1019
  • Development Phase of Primary Product:Phase II
Speakers
Karim Dabbagh
Second Genome
Back